Abstract 1279
Background
The newly created Department of Oncology Nurse Coordinators, in this case the Digestive Oncology department, ONCDOD, at the Jules Bordet Institute, allows patients, mainly the newly diagnosed, to early personalized medicine. The aim is to orient the patients to all the services available and implicated to his/her care; to explain the treatment, procedures for therapies and answer questions; to be present for the patient and his family so as to create a climate of confidence, comfort and security.
Methods
60 newly diagnosed digestive patients were followed by the Nurse Coordinator in the year 2018. The necessary care requirements for this group of patients were identified, recorded and analysed in collaboration with the multidisciplinary team. With the help of an exhaustive data on the patient, all the Oncology Nurse Coordinator’s activities were reported in a unique, accessible electronic patient’s file.
Results
Thanks to knowledge of the patient’s medical situation, but also to his psychological and socioeconomic environment, the interventions of the Oncology Nurse Coordinator allowed a more fluid path of diagnosis and treatment, rapid and efficient care of treatment side effects, avoid unnecessary hospitalization and ensure more comfort and security for the patient.
Conclusions
The daily follow-up of newly diagnosed digestive patients, allowed a more effective taking care of patients from the diagnosis. The patients showed confidence and serenity knowing that they can call one single person, anytime, in the hospital for all their questions and needs.
Clinical trial identification
Editorial acknowledgement
Legal entity responsible for the study
Fouad Awada.
Funding
Has not received any funding.
Disclosure
The author has declared no conflicts of interest.
Resources from the same session
3489 - Overall Survival (OS) and Metastasis-Free Survival (MFS) in men with Biochemically Relapsed (BCR) Prostate Cancer after radical prostatectomy (RP) managed with deferred Androgen Deprivation Treatment (ADT): A combined Johns Hopkins and CPDR study
Presenter: Catherine Marshall
Session: Poster Display session 3
Resources:
Abstract
4606 - ARCHES – the role of androgen deprivation therapy (ADT) with enzalutamide (ENZA) or placebo (PBO) in metastatic hormone-sensitive prostate cancer (mHSPC): Post hoc analyses of high and low disease volume and risk groups
Presenter: Arnulf Stenzl
Session: Poster Display session 3
Resources:
Abstract
2975 - Updated survival analyses of a multicentric phase II randomized trial of docetaxel (D) plus enzalutamide (E) versus docetaxel (D) as first line chemotherapy for patients (pts) with metastatic castration-resistant prostate cancer (mCRPC) (CHEIRON study).
Presenter: Orazio Caffo
Session: Poster Display session 3
Resources:
Abstract
2708 - Real-world analysis of patients (pts) with metastatic castration-resistant prostate cancer (mCRPC) receiving vs not receiving chemotherapy in the treatment sequence
Presenter: Alicia Morgans
Session: Poster Display session 3
Resources:
Abstract
2134 - Baseline fracture risk in men with prostate cancer starting the STAMPEDE trial
Presenter: Janet Brown
Session: Poster Display session 3
Resources:
Abstract
3504 - Risk of falls and fractures in patients with castration resistant prostate cancer (CRPC) treated with new hormonal agents – a meta-analysis of randomized controlled trials.
Presenter: Rodrigo Coutinho Mariano
Session: Poster Display session 3
Resources:
Abstract
2342 - Pain progression at initiation of chemotherapy in metastatic Castration-Resistant Prostate Cancer (mCRPC) is associated with a poor prognosis: a post-hoc analysis of FIRSTANA
Presenter: Nicolas Delanoy
Session: Poster Display session 3
Resources:
Abstract
5331 - Pain evaluation in patients (pts) with metastatic castration-resistant prostate cancer (mCRPC) treated with radium-223 (Ra-223) in the PARABO observation study
Presenter: Holger Palmedo
Session: Poster Display session 3
Resources:
Abstract
2823 - Time to castration resistant prostate cancer (CRPC) and the risk of developing immune disorders
Presenter: Vincenza Conteduca
Session: Poster Display session 3
Resources:
Abstract
1500 - Retrospective evaluation of neutropenic admission events in metastatic or high-risk hormone-sensitive prostate cancer (HSPC) patients having docetaxel chemotherapy upfront or for castrate-resistant prostate cancer (CRPC) in STAMPEDE
Presenter: Harriet Mintz
Session: Poster Display session 3
Resources:
Abstract